

Sanofi  
Form 6-K  
April 30, 2015

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

---

**For the month of April 2015**

**Commission File Number: 001-31368**

**SANOFI**

(Translation of registrant's name into English)

**54, rue La Boétie, 75008 Paris, FRANCE**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Edgar Filing: Sanofi - Form 6-K

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If  Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

## Edgar Filing: Sanofi - Form 6-K

In April 2015, Sanofi issued the statements attached hereto as Exhibits 99.1 to 99.6 which are incorporated herein by reference.

### Exhibit List

| <b>Exhibit No.</b> | <b>Description</b>   |
|--------------------|--|
| Exhibit 99.1       | Press release dated April 30, 2015: First Quarter 2015 Results   |
| Exhibit 99.2       | Press release dated April 28, 2015: Toujeo® Approved in the European Union for the Treatment of Diabetes in Adults   |
| Exhibit 99.3       | Press release dated April 28, 2015: FDA Grants Fast Track Designation to Genzyme's Investigational Substrate Reduction Therapy for the Treatment of Fabry Disease                          |
| Exhibit 99.4       | Press release dated April 23, 2015: Effect of Genzyme's Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activity Maintained Through Four Year |
| Exhibit 99.5       | Press release dated March 19, 2015: Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide)   |
| Exhibit 99.6       | Genzyme Product Sales Statement, for the Product Sales Measuring Period ended March 31, 2015   |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: April 30, 2015

SANOFI

By

/S/ John Felitti

Name:

John Felitti

Title:

Associate Vice President,  
Corporate Law, Financial & Securities  
Law

**Exhibit Index**

| <b>Exhibit No.</b> | <b>Description</b>   |
|--------------------|--|
| Exhibit 99.1       | Press release dated April 30, 2015: First Quarter 2015 Results   |
| Exhibit 99.2       | Press release dated April 28, 2015: Toujeo® Approved in the European Union for the Treatment of Diabetes in Adults   |
| Exhibit 99.3       | Press release dated April 28, 2015: FDA Grants Fast Track Designation to Genzyme's Investigational Substrate Reduction Therapy for the Treatment of Fabry Disease                          |
| Exhibit 99.4       | Press release dated April 23, 2015: Effect of Genzyme's Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activity Maintained Through Four Year |
| Exhibit 99.5       | Press release dated March 19, 2015: Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide)   |
| Exhibit 99.6       | Genzyme Product Sales Statement, for the Product Sales Measuring Period ended March 31, 2015   |